Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2949475rdf:typepubmed:Citationlld:pubmed
pubmed-article:2949475lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:2949475lifeskim:mentionsumls-concept:C0596002lld:lifeskim
pubmed-article:2949475lifeskim:mentionsumls-concept:C0143993lld:lifeskim
pubmed-article:2949475lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2949475lifeskim:mentionsumls-concept:C1705241lld:lifeskim
pubmed-article:2949475lifeskim:mentionsumls-concept:C0439097lld:lifeskim
pubmed-article:2949475lifeskim:mentionsumls-concept:C1547348lld:lifeskim
pubmed-article:2949475pubmed:issue7lld:pubmed
pubmed-article:2949475pubmed:dateCreated1987-3-4lld:pubmed
pubmed-article:2949475pubmed:abstractTextThe effect of sufentanil on somatosympathetic reflexes and the subsequent reversal of its effects by naloxone have been observed in dogs anaesthetised with alpha-chloralose, paralysed with suxamethonium and artificially ventilated. When the drug was infused at a rate of 2.5 micrograms kg-1 min-1 the late long latency response evoked by Group IV (C) fibres was totally abolished at a mean dose of 6.40 micrograms kg-1 (+/- 0.99 microgram kg-1) (s.e. mean), while retaining a substantial part of the early short latency response evoked by group III (A delta) fibres; subsequently, during the infusion, this response was also totally abolished at a mean dose of 26.2 micrograms kg-1 (+/- 3.2 mg kg-1). The administration of naloxone (2 mg i.v.) completely reversed the effects of sufentanil within 3-5 min in different preparations. Some of the implications of these results are discussed.lld:pubmed
pubmed-article:2949475pubmed:languageenglld:pubmed
pubmed-article:2949475pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2949475pubmed:citationSubsetIMlld:pubmed
pubmed-article:2949475pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2949475pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2949475pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2949475pubmed:statusMEDLINElld:pubmed
pubmed-article:2949475pubmed:monthOctlld:pubmed
pubmed-article:2949475pubmed:issn0001-5172lld:pubmed
pubmed-article:2949475pubmed:authorpubmed-author:WhitwamJ GJGlld:pubmed
pubmed-article:2949475pubmed:authorpubmed-author:Sapsed-ByrneS...lld:pubmed
pubmed-article:2949475pubmed:authorpubmed-author:ChakrabartiMMlld:pubmed
pubmed-article:2949475pubmed:authorpubmed-author:Odensjö...lld:pubmed
pubmed-article:2949475pubmed:issnTypePrintlld:pubmed
pubmed-article:2949475pubmed:volume30lld:pubmed
pubmed-article:2949475pubmed:ownerNLMlld:pubmed
pubmed-article:2949475pubmed:authorsCompleteYlld:pubmed
pubmed-article:2949475pubmed:pagination545-8lld:pubmed
pubmed-article:2949475pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:2949475pubmed:meshHeadingpubmed-meshheading:2949475-...lld:pubmed
pubmed-article:2949475pubmed:meshHeadingpubmed-meshheading:2949475-...lld:pubmed
pubmed-article:2949475pubmed:meshHeadingpubmed-meshheading:2949475-...lld:pubmed
pubmed-article:2949475pubmed:meshHeadingpubmed-meshheading:2949475-...lld:pubmed
pubmed-article:2949475pubmed:meshHeadingpubmed-meshheading:2949475-...lld:pubmed
pubmed-article:2949475pubmed:meshHeadingpubmed-meshheading:2949475-...lld:pubmed
pubmed-article:2949475pubmed:meshHeadingpubmed-meshheading:2949475-...lld:pubmed
pubmed-article:2949475pubmed:meshHeadingpubmed-meshheading:2949475-...lld:pubmed
pubmed-article:2949475pubmed:meshHeadingpubmed-meshheading:2949475-...lld:pubmed
pubmed-article:2949475pubmed:meshHeadingpubmed-meshheading:2949475-...lld:pubmed
pubmed-article:2949475pubmed:meshHeadingpubmed-meshheading:2949475-...lld:pubmed
pubmed-article:2949475pubmed:year1986lld:pubmed
pubmed-article:2949475pubmed:articleTitleSelective effect of sufentanil on group III (A delta) and group IV (C) somatosympathetic reflexes.lld:pubmed
pubmed-article:2949475pubmed:publicationTypeJournal Articlelld:pubmed